These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
168 related items for PubMed ID: 16359512
1. Modulation of TAFI function through different pathways--implications for the development of TAFI inhibitors. Gils A, Ceresa E, Macovei AM, Marx PF, Peeters M, Compernolle G, Declerck PJ. J Thromb Haemost; 2005 Dec; 3(12):2745-53. PubMed ID: 16359512 [Abstract] [Full Text] [Related]
2. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity. Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ. J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497 [Abstract] [Full Text] [Related]
3. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides. Plug T, Marquart JA, Marx PF, Meijers JC. J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360 [Abstract] [Full Text] [Related]
4. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a. Semeraro F, Ammollo CT, Gils A, Declerck PJ, Colucci M. J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522 [Abstract] [Full Text] [Related]
7. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. Mosnier LO. J Biol Chem; 2011 Jan 07; 286(1):502-10. PubMed ID: 21041299 [Abstract] [Full Text] [Related]
8. Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor. Hillmayer K, Vancraenenbroeck R, De Maeyer M, Compernolle G, Declerck PJ, Gils A. J Thromb Haemost; 2008 Nov 07; 6(11):1892-9. PubMed ID: 18752573 [Abstract] [Full Text] [Related]
9. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target. Satoh T, Satoh K, Yaoita N, Kikuchi N, Omura J, Kurosawa R, Numano K, Al-Mamun E, Siddique MA, Sunamura S, Nogi M, Suzuki K, Miyata S, Morser J, Shimokawa H. Circ Res; 2017 Apr 14; 120(8):1246-1262. PubMed ID: 28289017 [Abstract] [Full Text] [Related]
17. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. Ceresa E, Van de Borne K, Peeters M, Lijnen HR, Declerck PJ, Gils A. J Biol Chem; 2006 Jun 09; 281(23):15878-83. PubMed ID: 16595693 [Abstract] [Full Text] [Related]
19. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model. Vercauteren E, Emmerechts J, Peeters M, Hoylaerts MF, Declerck PJ, Gils A. Blood; 2011 Apr 28; 117(17):4615-22. PubMed ID: 21343611 [Abstract] [Full Text] [Related]
20. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Binette TM, Taylor FB, Peer G, Bajzar L. Blood; 2007 Nov 01; 110(9):3168-75. PubMed ID: 17644733 [Abstract] [Full Text] [Related] Page: [Next] [New Search]